By integrating those approaches, our strategy concentrates therapeutic activity within tumors, remodels the tumor microenvironment to convert “cold” tumors into “hot” ones, reduces systemic toxicity, and aims to replace costly multi-drug regimens with multifunctional, scalable therapies capable of achieving durable cancer control.
 
Our group maintains a strong research program in applied genomics, with a focus on underrepresented populations. A flagship initiative is the Molecular Profile of Breast Cancer Study (MPBCS), conducted within the Latin American Cancer Research Network (LACRN), which collected molecular, clinical, and epidemiological data from over 1,200 patients across Latin America. These studies characterized disease-relevant features including transcriptomic and molecular signatures, genetic ancestry, and socio-economic, clinical, and molecular determinants of disease. Similar approaches have been applied to rectal cancer and extended to a clinical and genetic study of Argentine patients with Stargardt disease.

We engineered a novel vaccine platform based on a chimeric human adenovirus 5 (hAdV5) vector. The vaccine platform (named CoroVaxG.3) was based on three pillars: (i) high expression of Spike to enhance its immunodominance by using a potent promoter and an mRNA stabilizer; (ii) enhanced infection of muscle and dendritic cells by replacing the fiber knob domain of hAdV5 by hAdV3; (iii) use of Spike stabilized in a prefusion conformation. We observed the development of cellular and humoral response and that nAbs did not wane even after 5 months. Administration of a novel version CorovaxG.3-D.FR in a prime/boost regimen showed that a booster was able to increase the neutralizing capacity of the sera against all variants and fully protect aged K18-hACE2 mice against Omicron BA.1, as a BA.1-targeted vaccine did (see articles below).